Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
Amyloidosis Ireland, Derry, Ireland.
BMJ Open. 2023 Sep 5;13(9):e073130. doi: 10.1136/bmjopen-2023-073130.
Hereditary transthyretin-mediated amyloidosis is a rare, progressive and potentially life-limiting multisystem disease, affecting every aspect of a patient's life.
This online international Delphi survey aimed to evolve clinical-patient-led practical guidance, to inspire and encourage a holistic approach to care that is managed in specialist settings by multidisciplinary teams and supported by allied healthcare professionals (HCPs) and patient advocacy groups (PAGs).
A 14-member joint patient advocate-HCP primary panel was convened including representation from PAGs and key clinical specialties (neurology, cardiology, internal medicine, physiotherapy, clinical psychology, dietetics and specialist nursing). Guidance evolved on the care provision needed to support seven core goals: early diagnosis and treatment; disease monitoring and organisation of care; maintenance of physical and mental health; family-centred care and caregiver support; patient-doctor dialogue; access to social support and social networking.
From June to October 2022, 252 HCPs and 51 PAG representatives from 27 countries were invited to participate in a Delphi survey. Of the 122 respondents who answered at least one survey question, most were HCPs (100, 82%) from specialist centres; the remainder were PAG representatives (22, 18%).
Both level of agreement and feasibility in practice of each recommendation was tested by two anonymised online Delphi voting rounds.
Based on an a priori threshold for consensus of ≥75% agreement, the clinical-patient community endorsed all but one recommendation. However, only 17/49 (35%) recommendations were identified by most HCPs as a core part of routine care; the remainder (32/49 (65%)) were identified as part of core care by <50% of HCPs respondents, or as largely achievable by 30%-45% of HCPs. By comparison, PAGs recorded lower implementation levels.
Further consideration is needed on how to evolve multidisciplinary services (supported by allied HCPs and PAGs) to address the complex needs of those affected by this disease.
遗传性转甲状腺素蛋白介导的淀粉样变性是一种罕见的、进行性的、潜在危及生命的多系统疾病,影响患者生活的方方面面。
本项在线国际 Delphi 调查旨在制定以临床-患者为导向的实用指南,为多学科团队在专科环境中管理疾病提供灵感和鼓励,倡导采取整体护理方法,并得到相关医疗保健专业人员(HCPs)和患者倡导团体(PAGs)的支持。
召集了一个由 14 名联合患者倡导-HCP 主要专家组成的小组,包括 PAGs 和关键临床专业(神经病学、心脏病学、内科、物理治疗、临床心理学、营养学和专科护理)的代表。该指南主要涉及支持以下 7 个核心目标所需的护理内容:早期诊断和治疗;疾病监测和护理组织;维持身心健康;以家庭为中心的护理和照顾者支持;医患对话;获得社会支持和社交网络。
2022 年 6 月至 10 月,邀请了来自 27 个国家的 252 名 HCPs 和 51 名 PAG 代表参加 Delphi 调查。在回答了至少一个调查问题的 122 名受访者中,大多数是来自专科中心的 HCPs(100,82%);其余是 PAG 代表(22,18%)。
通过两轮匿名在线 Delphi 投票,分别对每条建议的共识程度和实践可行性进行了测试。
根据≥75%的共识率的预设标准,临床-患者群体认可了除一项建议外的所有建议。然而,只有 17/49(35%)的建议被大多数 HCPs 认为是常规护理的核心部分;其余 32/49(65%)的建议被不到 50%的 HCPs 受访者认为是核心护理的一部分,或者被 30%-45%的 HCPs 认为是基本可以实现的。相比之下,PAGs 的实施水平较低。
需要进一步考虑如何发展多学科服务(得到相关 HCPs 和 PAGs 的支持),以满足受这种疾病影响的人群的复杂需求。